Eli Lilly Cuts Sales Outlook After Sluggish Growth for Incretin Drugs
Eli Lilly cut its outlook for fourth-quarter revenue citing sluggish growth in the market for incretin, which increases ...
Eli Lilly Buys Cancer Therapy And Announces Timing Of Weight Loss Pill
Pharmaceutical giant Eli Lilly & Co. (LLY) is buying privately held Scorpion Therapeutics’ experimental cancer therapy for $2 ...
6LLY : Eli Lilly Cuts Q4 Revenue Guidance, Expects Around $5...
Eli Lilly expects 2024 revenue of $45.0 billion, reflecting a 32% increase, with strong contributions from Mounjaro and ...
Eli Lilly Cuts Q4 Revenue Guidance, Expects Around $5.5 Billion Sales From Weight Loss ...
Eli Lilly and Co (NYSE: LLY) announced that it expects 2024 full-year worldwide revenue to be approximately $45.0 billion, ...
Lilly Sales Miss on Slower-Than-Expected Obesity Shot Demand
Eli Lilly & Co. reported preliminary fourth-quarter revenue that missed analyst estimates on lower-than-expected sales of its ...
Lilly forecasts weak sales of weight-loss drug in fourth quarter
Eli Lilly expects sales of popular weight-loss drug Zepbound and related diabetes treatment Mounjaro to miss Wall Street ...
Eli Lilly shares drop as drugmaker cuts revenue guidance on weight loss drug demand
Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity ...
Lilly forecasts weak fourth-quarter sales of weight-loss drug, shares slump
Eli Lilly forecast sales of popular weight-loss drug Zepbound and related diabetes treatment Mounjaro to miss Wall Street ...
Mounjaro and Zepbound sales disappoint, and Eli Lilly’s stock is dropping
Shares of Eli Lilly and Co. slipped 0.4% in premarket trading Tuesday, after the drug maker provided a disappointing fourth-quarter revenue outlook, citing slower-than-expected growth in sales of its ...
Yahoo Finance1 小时
Lexaria's Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half with Comparable ...
Blood glucose reduction and insulin secretion levels from the oral DehydraTECH-tirzepatide were comparable to injected Zepbound® KELOWNA, BC / ACCESSWIRE / January 14, 2025 / Lexaria Bioscience ...
礼来公司预计2024年收入增长32%，2025年指引上调
印第安纳波利斯 - 目前市值超过7,180亿美元，交易价格高于其 InvestingPro 公允价值的礼来公司（NYSE:LLY）今日宣布，预计2024年全年收入将达到约450亿美元，较上年显著增长32%。这家制药巨头保持着令人印象深刻的80.9%的毛利率，同时预测2025年收入将在580亿美元至610亿美元之间，显示出持续的增长势头。